An interventional study of bupivacaine and dexamethasone in Cesarean Section, sponsored by Aswan University Hospital. Completed at 1 site in Egypt. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2020-08-05.
Sponsored by Aswan University Hospital · Not applicable, Interventional, and Prevention
Our aim to study the efficacy of bupivacaine 0.25% with dexamethasone and that of bupivacaine 0.25% alone in transversus abdominis plane (TAP) block for postoperative analgesia in patients undergoing an elective Caesarean section.
The pain and discomfort following cesarean delivery are mostly due to the abdominal wall incision and dissection of muscles; it delays early ambulation and breastfeeding. This can lead to postoperative complications such as thromboembolic disorders. So, providing an effective and safe postoperative analgesic method seems to be mandatory. Opioid analgesia remains the most effective means of relieving pain in a wide variety of conditions; however, it may cause adverse effects such as nausea, vomiting, pruritus, urinary retention, and respiratory depression. As the analgesia and the side effects of opioids are dose-dependent, a multimodal approach may enhance analgesia, which in turn would decrease the side effects .
Mc Donnell and colleagues have reported that a transversus abdominis plane (TAP) block can decrease the postoperative pain following abdominal surgery. The landmarks of this block were first described in 2001 by Rafi. The TAP block has been performed for postoperative analgesic control in patients undergoing radical prostatectomy, hysterectomy, cesarean delivery under spinal anesthesia, and laparoscopic surgery.
Aswan University Hospital is the lead sponsor of 95 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Bilateral TAP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
Drug: bupivacaine · Drug: dexamethasone
BilateralTAP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
Drug: bupivacaine · Drug: placebo to dexamethasone
TAP block with 20 ml of 0.25% bupivacaine bilaterally
Also known as: Active Comparator
TAP block with 4 mg dexamethasone bilaterally
Also known as: active comparator
TAP block with 4 mg placebo to dexamethasone bilaterally
Also known as: Placebo
Visual analog score for pain during movement
movement-evoked pain measurements ranging from 0 to 10, where 0 no pain and 10 maximum pain
Time frame: 6 hours post operative
Visual analog score during rest
ranging from 0 to 10, where 0 no pain and 10 maximum pain
Time frame: 48 hours postoperative
number of patients need Fentanyl consumption
number of patients need Fentanyl consumption
Time frame: 48 hours postoperative
number of days patients stay in hospital
calculation of number of days patients stay in hospital
Time frame: 4 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aswan University Hospital